Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b placebo-controlled study of IMVT-1402 in CIDP
NL-OMON60391Phase 2Recruiting
- Sponsor
- Immunovant, Inc.
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of IMVT-1402 in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Immunovant, Inc. Started Feb 2026; status: recruiting.
02
Drugs
IMVT-1402
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NL-OMON60391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60391.